Anti-tumor mechanism of soluble form of sialic acid-recognizing protein, Siglec-9
Project/Area Number |
26450398
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Veterinary medical science
|
Research Institution | Tottori University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
森松 正美 北海道大学, 獣医学研究科, 准教授 (70241370)
小野 悦郎 九州大学, 医学研究院, 教授 (00160903)
|
Research Collaborator |
TAKEUCHI Takashi
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 疾患モデルマウス / 病態 / 腫瘍 / シアル酸認識レクチン / ムチン / トランスジェニックマウス / 疾患モデル動物 / 腫瘍免疫 / シアル酸結合レクチン / 糖タンパク質 / 乳癌 / 卵巣癌 / 抗病性動物 / 発生工学 |
Outline of Final Research Achievements |
It was revealed that proliferation and malignant transformation of MUC1-positive tumor were prevented in the transgenic mice expressing a soluble form of sialic acid-binding immunoglobulin-like lectin 9 (sSiglec-9). In addition, it was suggested that this anti-tumor mechanism indirectly acted through the immune system of the host. On the other hand, sSiglec-9 acivated a proliferation of MUC16-positive tumor rather than inhibited, surprisingly. According to the above results, it was shown Siglec-9 interacted with the mucin expressed in tumor and to participate in a tumor proliferation and malignant transformation. These knowledge make the beginning to found the molecular targeted therapy for cancers through Siglec-9.
|
Report
(4 results)
Research Products
(3 results)